Mode
Text Size
Log in / Sign up
Phase 3 Completed N=2,032 Treatment

Efficacy, Safety and Tolerability Study of Agile AG200-15 Transdermal Contraceptive Delivery System

Healthy
Source: ClinicalTrials.gov NCT02158572 ↗
Enrolled (actual)
2,032
Serious AEs
2.0%
Results posted
Sep 2017
Primary outcomePrimary: Contraception Efficacy of AG200-15 in Subjects ≤ 35 Years of Age Regardless of BMI, Intent-to-treat (ITT) Dataset. — 5.80 Pearl Index
◆ Published Evidence
Established
32citations · ~6 / year
Efficacy, safety, and tolerability of a levonorgestrel/ethinyl estradiol transdermal delivery system: Phase 3 clinical trial results.
Contraception · 2021 · Open access · Likely link

Summary

Study of the efficacy of a contraceptive patch in 2100 healthy women for up to one year.

Linked Publications

  • Efficacy, safety, and tolerability of a levonorgestrel/ethinyl estradiol transdermal delivery system: Phase 3 clinical trial results.
    Contraception · 2021 · 32 citations · Open access · Likely link

Outcome Measures

OutcomeResultp-value
PRIMARY
Contraception Efficacy of AG200-15 in Subjects ≤ 35 Years of Age Regardless of BMI, Intent-to-treat (ITT) Dataset.
5.80
SECONDARY
Contraception Efficacy of AG200-15 in Subjects ≤ 35 Years of Age With BMI < 25 kg/m2, ITT Dataset
3.5
SECONDARY
Contraception Efficacy of AG200-15 in Subjects ≤ 35 Years of Age With BMI ≥ 25 and < 30 kg/m2, ITT Dataset
5.7
SECONDARY
Contraception Efficacy of AG200-15 in Subjects ≤ 35 Years of Age With BMI ≥ 30 kg/m2, ITT Dataset
8.6

Eligibility Criteria

Inclusion Criteria

  • Healthy, sexually active woman at risk for pregnancy seeking to use hormonal contraception for at least 1 year
  • Ability to demonstrate willingness to participate and adhere to study protocol

Exclusion Criteria

  • Known or suspected pregnancy
  • Lactating women
  • Anticipates use of condoms or any other form of back-up contraception during the study
  • History of dermal sensitivity to medicated patches (nicotine) or to bandages, surgical tape, etc.
  • Has a contraindication to combined estrogen-progestin contraceptive use
  • Any disease that may worsen under hormonal treatment (cardiovascular, liver, metabolic)
  • Smoker who is 35 years old or over
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02158572) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search